Building a Global Manufacturing Network: "Dual-Sourcing" Commercial Strategies

FDA approval does not settle the question of EU readiness. For biologics, differing regulatory expectations, Qualified Person (QP) release requirements, importation pathways, and manufacturing networks spread across regions can all put launch timing and supply continuity at risk.

Drawing on real-world EU launch experience, the experts in this session examine how organizations design commercial supply strategies before problems surface, and how manufacturing, quality, and supply chain functions can stay aligned across regions.

Listen in to hear what those launch lessons mean for readiness, scalability, and ongoing supply.